Article
Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Cancer research - 15 Feb 2012
Su Fei, Bradley William D, Wang Qiongqing, Yang Hong, Xu Lizhong, Higgins Brian, Kolinsky Kenneth, Packman Kathryn, Kim Min Jung, Trunzer Kerstin, Lee Richard J, Schostack Kathleen, Carter Jade, Albert Thomas, Germer Soren, Rosinski Jim, Martin Mitchell, Simcox Mary Ellen, Lestini Brian, Heimbrook David, Bollag Gideon
Abstract excerpt
A high percentage of patients with BRAF(V600E) mutant melanomas respond to the selective RAF inhibitor vemurafenib (RG7204, PLX4032) but resistance eventually emerges. To better understand the mechanisms of resistance, we used chronic selection to establish BRAF(V600E) melanoma clones with acquired resistance to vemurafenib. These clones retained the V600E mutation and no second-site mutations were identified in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.